Neurolixis Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Neurolixis Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11258
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Neurolixis Inc (Neurolixis) is an early-stage biopharmaceutical company that discovers and develops novel drugs for the treatment of human central nervous system disorders. The company’s pipeline product portfolio includes NLX-112, a drug candidate intended for the treatment of L-DOPA-induced dyskinesia; and NLX-101 is a drug used for the treatment of breathing difficulties in Rett’s syndrome, a genetically-encoded orphan disorder. Neurolixis therapeutic focus include pre-clinical drug discovery and early clinical development of candidates targeting unmet needs in the field of neurological and neuropsychiatric illness. The company offers treatment solutions for human central nervous system disorders such as Parkinson’s disease, Rett syndrome, depression and schizophrenia. Neurolixis is headquartered in Dana Point, California, the US.

Neurolixis Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurolixis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Neurolixis Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Neurolixis Raises US$0.01 Million In Venture Financing Round 10
Partnerships 11
Neurolixis Enters into Co-Development Agreement with Jagiellonian University Medical College 11
Licensing Agreements 12
Neurolixis Enters Into Licensing Agreement With Pierre Fabre Medicament 12
Neurolixis Inc – Key Competitors 14
Neurolixis Inc – Key Employees 15
Neurolixis Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Government and Public Interest 17
Nov 23, 2017: Neurolixis showcased online by “LaBiotech” 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Neurolixis Inc, Pharmaceuticals & Healthcare, Key Facts 2
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurolixis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurolixis Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Neurolixis Raises US$0.01 Million In Venture Financing Round 10
Neurolixis Enters into Co-Development Agreement with Jagiellonian University Medical College 11
Neurolixis Enters Into Licensing Agreement With Pierre Fabre Medicament 12
Neurolixis Inc, Key Competitors 14
Neurolixis Inc, Key Employees 15

List of Figures
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Neurolixis Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • BioGaia AB (BIOG B):製薬・医療:M&Aディール及び事業提携情報
    Summary BioGaia AB (BioGaia) is a biopharmaceutical company, which develops, markets and sells probiotic products. The company sells its probiotic food supplements and oral health products in various dosage forms including drops, lozenges, tablets, chewable tablets, oral rehydration salts (ORS), str …
  • Metacrine Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Metacrine Inc (Metacrine) is a clinical-stage biopharmaceutical company that focuses on the development of therapies for the treatment of patients with liver and gastrointestinal diseases. The company develops its proprietary portfolio of non-bile acid FXR agonists through its chemistry and …
  • Cyclenium Pharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Cyclenium Pharma Inc (Cyclenium Pharma) is a pharmaceutical research and development company that offers small molecule therapeutics agent producer for drug discovery. The company employs its proprietary customized macrocycles for recognition of topologies technology for discovering and deve …
  • Parkson Retail Group Ltd:企業の戦略・SWOT・財務情報
    Parkson Retail Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Parkson Retail Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Air Transport Services Group, Inc.:企業の戦略・SWOT・財務情報
    Air Transport Services Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Air Transport Services Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • AnaBios Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary AnaBios Corp (AnaBios) is a pre-clinical stage contract research organization that offers drug efficacy studies on human samples. The organization’s products portfolio includes human dorsal root ganglia neuron cultures, human cardiac mesenchymal stem cells, human heart tissue samples, human …
  • CardioGenics Inc:企業の製品パイプライン分析2018
    Summary CardioGenics Inc (CardioGenics), a subsidiary of CardioGenics Holdings Inc is a medical device company that manufactures sensitive diagnostic test products to the in-vitro diagnostics market. The company’s products include QL care analyzer, immunoassay tests, and paramagnetic beads, among ot …
  • Data Respons ASA (DAT):企業の財務・戦略的SWOT分析
    Summary Data Respons ASA (Data Respons) is an information technology company that offers software products and embedded solutions. The company's products include storage and memory, handheld tablets, embedded boards, panel PCs and displays, systems and platforms, and industrial communication product …
  • Lamprell Plc (LAM):企業の財務・戦略的SWOT分析
    Lamprell Plc (LAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Aohata Corporation:企業の戦略・SWOT・財務情報
    Aohata Corporation - Strategy, SWOT and Corporate Finance Report Summary Aohata Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Kroton Educacional S.A. (KROT3):企業の財務・戦略的SWOT分析
    Kroton Educacional S.A. (KROT3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • NanoBio Corp-製薬・医療分野:企業M&A・提携分析
    Summary NanoBio Corp (NanoBio) is a biopharmaceutical company that develops vaccines. The company develops and commercializes intranasal and intramuscular vaccines for the prevention and treatment of infectious diseases. The company's vaccines include anthrax, H5 influenza, pertussis, RSV, HIV, HSV- …
  • Huhtamaki Oyj:企業の戦略・SWOT・財務情報
    Huhtamaki Oyj - Strategy, SWOT and Corporate Finance Report Summary Huhtamaki Oyj - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • The Sherwin-Williams Company:企業の戦略・SWOT・財務情報
    The Sherwin-Williams Company - Strategy, SWOT and Corporate Finance Report Summary The Sherwin-Williams Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Statnett SF:電力:M&Aディール及び事業提携情報
    Summary Statnett SF (Statnett) transmits and distributes high voltage electricity in Norway primarily generated from its hydro-electric power plants. It operates as a system operator in the Norwegian energy system. The company is a state enterprise, established under the Act relating to state-owned …
  • Tobu Railway Co Ltd:戦略・SWOT・企業財務分析
    Tobu Railway Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Tobu Railway Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • UnionBank of the Philippines (UBP):企業の財務・戦略的SWOT分析
    UnionBank of the Philippines (UBP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Bharat Heavy Electricals Ltd (BHEL):企業の財務・戦略的SWOT分析
    Bharat Heavy Electricals Ltd (BHEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • ContraFect Corp (CFRX):製薬・医療:M&Aディール及び事業提携情報
    Summary ContraFect Corp (ContraFect) is a clinical stage biotechnology company that discovers and develops therapeutic protein and antibody products. The company develops products using lysin and monoclonal antibody platforms for the treatment of life threatening, drug-resistant infectious diseases. …
  • Cemat AS (CEMAT):企業の財務・戦略的SWOT分析
    Cemat AS (CEMAT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆